Safety and effectiveness of dofetilide for conversion of atrial fibrillation and nesiritide for acute decompensation of heart failure: a report from the cardiovascular and renal advisory panel of the Food and Drug Administration.
Grines
C L
CL
William Beaumont Hospital, Royal Oak, MI 48073-6769, USA. cgrines@beaumont.edu
D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D009320:Atrial Natriuretic Factor / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D010627:Phenethylamines / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D026902:Potassium Channel Blockers; D013449:Sulfonamides / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D013810:Therapeutic Equivalency
D000889:Anti-Arrhythmia Agents; D002317:Cardiovascular Agents; D010627:Phenethylamines; D026902:Potassium Channel Blockers; D013449:Sulfonamides; D009320:Atrial Natriuretic Factor; C063533:dofetilide